Dermatologists crucial to managing side effects of EGFR inhibitor for NSCLC
09 Nov 2020
byTristan Manalac
The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of nonsmall cell lung cancer (NSCLC) commonly triggers cutaneous side effects, which often leads to drug reductions or discontinuation, reports a new study at the recently concluded 2020 Virtual Congress of the European Academy of Dermatology and Venereology (EADV 2020).
